MYCN and prostate cancer: Such as, in myogenic cells, miR-133a could promote myogenic cell proliferation and skeletal muscle development by controlling serum response factor (SRF) and transforming growth factor beta receptor 1 (TGFβR1) expression [31]; miR-145-5p could target SRY-box transcription factor 11 (SOX11) gene and function in tumor-suppressive roles, then to further mediate MYCN proto-oncogene, bHLH transcription factor (MYCN) gene during neuroendocrine differentiation of prostate cancer cells [32].